

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/6729420>

Pterulamides I–VI, Linear Peptides from a Malaysian *Pterula* sp.

ARTICLE *in* JOURNAL OF NATURAL PRODUCTS · NOVEMBER 2006

Impact Factor: 3.8 · DOI: 10.1021/np0600245 · Source: PubMed

CITATIONS

5

READS

31

8 AUTHORS, INCLUDING:



Laily B. Din

National University of Malaysia

59 PUBLICATIONS 696 CITATIONS

SEE PROFILE



Vikineswary Sabaratnam

University of Malaya

224 PUBLICATIONS 1,528 CITATIONS

SEE PROFILE



Noorlidah Abdullah

University of Malaya

150 PUBLICATIONS 918 CITATIONS

SEE PROFILE



John Blunt

University of Canterbury

251 PUBLICATIONS 10,133 CITATIONS

SEE PROFILE

Pterulamides I–VI, Linear Peptides from a Malaysian *Pterula* sp.

Gerhard Lang,[†] Maya I. Mitova,[†] Anthony L. J. Cole,[‡] Laily B. Din,[§] Sabaratnam Vikineswary,[⊥] Noorlidah Abdullah,[⊥] John W. Blunt,[†] and Murray H. G. Munro^{*,†}

Department of Chemistry and School of Biological Sciences, University of Canterbury, Private Bag 4800, Christchurch, New Zealand, School of Chemical Sciences and Food Technology, Universiti Kebangsaan Malaysia, 43600 Bangi, Selangor, Malaysia, and Institute of Biological Sciences, University of Malaya, 50603 Kuala Lumpur, Malaysia

Received January 16, 2006

Six new linear peptides, pterulamides I–VI (**1**–**6**), were isolated from the fruiting bodies of a Malaysian *Pterula* species. The structures were elucidated by MS and 2D NMR experiments, and the absolute configurations of the constituent amino acids established using Marfey's method. The pterulamides are mainly assembled from nonpolar *N*-methylated amino acids and, most interestingly, have non-amino-acid *N*-terminal groups, among them the unusual cinnamoyl, (*E*)-3-methylsulfinylpropenoyl, and (*E*)-3-methylthiopropenoyl groups. Furthermore, pterulamides I–V are the first natural peptides with a methylamide *C*-terminus. Pterulamides I and IV are cytotoxic against the P388 cell line with IC₅₀ values of 0.55 and 0.95 $\mu\text{g/mL}$ (0.79 and 1.33 μM), respectively.


Fungi of the genus *Pterula* (family Clavariaceae) are clavarioid basidiomycetes with predominantly coral-shaped fruiting bodies. A great variety of *Pterula* species occur from temperate to tropical regions,¹ but relatively little is known about the chemistry of these fungi. The only strain investigated, *Pterula* sp. 82168, was shown to produce the previously unknown natural products hydroxystrobilurin A,² pterulones A and B,^{3,4} pterulinic acid,³ and noroude-mansin A,⁵ all of which were strongly bioactive.

In this paper we describe the isolation, structural elucidation, and biological activities of six novel linear peptides, pterulamides I–VI (**1**–**6**), from the fruiting bodies of a Malaysian *Pterula* sp. These compounds are remarkable not only for their high degree of *N*-methylation but because they also contain unusual, or unprecedented, *N*-terminal groups, viz., benzoyl, cinnamoyl, (*E*)-3-methylsulfinylpropenoyl, and (*E*)-3-methylthiopropenoyl. A further structural feature hitherto unknown from natural peptides is the methylamide *C*-terminus found in pterulamides I–V.

Results and Discussion

Methanol extracts of two Malaysian *Pterula* sp. collections (A and B) exhibited strong cytotoxicity against P388 murine leukemia cells. Careful LC-MS and HPLC analyses of these two extracts indicated elements of similarity and differences between them. Six major components were identified by HPLC, and these compounds, pterulamides I–IV (**1**–**6**), were isolated using preparative HPLC. Compound **1** was present in extracts from both collections (A and B), while **2**, **3**, and **4** were found only in the extract of collection B, and **5** and **6** only in collection A. The ¹H NMR spectra of all six compounds (**1**–**6**) suggested *N*-methylated valyl, leucyl, or isoleucyl amino acid residues.

HRESIMS data for pterulamide I (**1**) indicated a molecular formula of C₃₄H₆₂N₆O₇S. The ¹H NMR spectrum, which displayed doubled signals for several sets of resonances, showed signals for the α -protons of five amino acids. These proved to be a convenient starting point for the identification of the individual amino acid units by COSY, TOCSY, HSQC, and HMBC experiments (see Table 1). Thus, one alanine, two valine, and two isoleucine residues were identified. Between 2.6 and 3.2 ppm in the ¹H NMR spectrum were six methyl groups, four of which from evaluation of the



HMBC correlations could be attributed to *N*-methylation of the alanine, the two isoleucine, and one of the valine units. A fifth methyl group, a doublet at 2.69 ppm with a coupling constant of 4.0 Hz, showed a long-range *H,C*-coupling to the carbonyl carbon of one of the isoleucine units and *H,H*-coupling to an amide proton. It was concluded that this methyl group belonged to a *C*-terminal methylamide group. This was supported by the ESIMS, which showed an $[M - \text{NHMe}]^+$ ion. There remained three signals in

* Corresponding author. Tel: +64-3-3642434. Fax: +64-3-3642429. E-mail: murray.munro@canterbury.ac.nz.

[†] Department of Chemistry, University of Canterbury.

[‡] School of Biological Sciences, University of Canterbury.

[§] Universiti Kebangsaan Malaysia.

[⊥] University of Malaya.


Table 1. NMR Data of Pterulamide I (**1**) in MeOH- d_4

| position | δ_C^a | δ_H (J in Hz) | COSY | HMBC | TOCSY | ROESY |
|-------------------|--------------|---------------------------|-----------------------------------|--|----------------------------------|---|
| MSP ^b | | | | | | |
| CO | 165.7 | | | | | |
| α | 126.3 | 7.13 d (14.5) | β | CO, β , SO-Me | β | Ala-NMe, Ile1- α |
| β | 149.4 | 7.64 d (14.5) | α | CO, α | α | SO-Me |
| SO-Me | 39.6 | 2.76 s ^c | | β | β | |
| Ala | | | | | | |
| CO | 174.1 | | | | | |
| α | 51.6 | 5.38 q (7.0) ^c | β | CO, β , NMe, MSP-CO | β | β , Ile1-NMe |
| β | 14.5 | 1.34 d (7.0) ^c | α | CO, α | α | α , NMe |
| N-Me | 31.7 | 3.15 s ^c | | α , MSP-CO | | β , MSP- α |
| Ile1 ^d | | | | | | |
| CO | 173.0 | | | | | |
| α | 58.3 | 5.22 d (11.0) | β | CO, β , β -Me, γ , Ala-CO | β , β -Me, γ | MSP- α |
| β | 34.2 | 2.16 m | α , γ , β -Me | | α , β -Me, γ | Val1-NMe, β -Me, γ |
| β -Me | 15.7 | 0.86 | β | | α , β , γ | α , NMe |
| γ | 25.2 | 1.01 + 1.40 m | β | δ , β -Me | α , β , β -Me | α |
| δ | 10.7 | 0.89 | | | | |
| N-Me | 30.6 | 3.05 s | | α , Ala-CO | | β , Ala- α , Val1- γ' |
| Val1 ^d | | | | | | |
| CO | 171.7 | | | | | |
| α | 63.4 | 4.63 d (11.0) | β | CO, β , γ , γ' , NMe, Ile1-CO | β , γ , γ' | γ , γ' |
| β | 27.6 | 2.24 m | α , γ , γ' | α , γ , γ' | α , γ , γ' | NMe |
| γ | 19.2 | 0.86 | β | | α , β , γ' | α , NMe |
| γ' | 18.6 | 0.76 d (6.5) | β | α , β , γ | α , β , γ | α , NMe, Ile1-NMe |
| N-Me | 31.4 | 3.10 s | | α , Ile1-CO | | β , γ , γ' , Ile1- α |
| Val2 ^d | | | | | | |
| CO | 174.3 | | | | | |
| α | 55.8 | 4.57 m | β , NH | CO, β , γ/γ' , Val1-CO | β , γ/γ' | γ , γ' , Ile2-NMe |
| β | 31.9 | 2.04 m | α , γ , γ' | α , γ/γ' | α , γ/γ' | |
| γ | 18.7 | 0.90 | β | α , β , γ' | α , β | α |
| γ' | ~19 | 0.86 | β | | α , β | α |
| NH | | 8.15 d (8.0) | α | | | |
| Ile2 ^d | | | | | | |
| CO | 172.7 | | | | | |
| α | 61.6 | 4.72 d (11.5) | β | CO, β , β -Me, γ , NMe, Val2-CO | β , β -Me, γ | β -Me, γ |
| β | 33.0 | 2.07 m | α , γ | | α , β -Me, γ | NMe |
| β -Me | 15.4 | 0.86 | | | α , β , γ | NMe |
| γ | 25.2 | 0.95 + 1.35 m | β | δ , β -Me | α , β , β -Me | α |
| δ | 10.5 | 0.84 | | | | |
| N-Me | 31.3 | 3.18 s | | α , Val2-CO | | β , β -Me, Val2- α |
| CONH | | 7.93 m | CONHMe | | | |
| CONHMe | 25.7 | 2.69 d 4.0 | CONH | CO | | |

^a ^{13}C shifts are taken from the HMBC spectrum. ^b MSP = (*E*)-3-methylsulfinylpropenoyl residue. ^c Signals doubled, due to mixture of diastereomers. ^d Similar amino acids are numbered consecutively from *N*- to *C*-terminal end.

the ^1H NMR spectrum not accounted for by the five amino acid units and the *C*-terminal methylamide end group. These signals were the sixth methyl group (2.76 ppm) and two doublets (7.13 and 7.64 ppm). The doublet signals belonged to an *E*-alkene ($^3J_{\text{HH}}$ 14.5 Hz), with both protons showing long-range *H,C*-coupling to a carbonyl carbon at 165.7 ppm. The sixth methyl group showed long-range *H,C*-coupling to just one of the alkene carbons (149.4 ppm). The formula $\text{C}_4\text{H}_5\text{O}_2\text{S}$ for the unassigned fragment of the assumed molecular formula, the long-range *H,C*-couplings, and the chemical shift values were consistent only with an (*E*)-3-methylsulfinylpropenoyl group at the *N*-terminus of the peptide. This also explained the doubled ^1H NMR signals observed for the MeSO-group and all protons of the *N*-methyl alanine unit, caused by a 1:1 mixture of diastereomers differing only in the configuration of the methylsulfinyl group.

The sequence of the five amino acid units in **1** was established mainly by evaluation of long-range *H,C*-couplings of the *N*-methyl groups (Figure 1), but was also supported by ROESY correlations and the fragmentation in ESIMS. The *C*-terminal position of an *N*-methylisoleucine unit (Ile2 in Table 1) was apparent from the coupling of the methylamide group to the carbonyl carbon of this amino acid and the *N*-methyl group of Ile2 coupled to the carbonyl carbon of the non-*N*-methylated valine (Val2). From the *N*-terminus the fragment 3-methylsulfinylpropenoyl-NMe-Ala-NMe-Ile-NMe-Val was likewise established by long-range *H,C*-couplings of each *N*-methyl group to the carbonyl carbon of the respective

**Figure 1.** Long-range *H,C*-couplings and ESIMS fragments indicative of the amino acid sequence of **1**.

next amino acid unit. The connection between the *N*-methylated and the non-methylated valine units (Val1 and Val2) was not supported by NMR data but follows inevitably from the presented substructures, as it is the only possibility for joining the two fragments together. The proposed pentapeptidic structure was 3-methylsulfinylpropenoyl-NMe-Ala-NMe-Ile-NMe-Val-NH-Val-NMe-Ile-NHMe. The ESIMS was in agreement with this structure, showing the fragment ions $[\text{M} - \text{NHMe}]^+$, $[\text{M} - (\text{NH-Val-NMe-Ile-NHMe})]^+$, and $[\text{M} - (\text{NMe-Val-NH-Val-NMe-Ile-NHMe})]^+$.

The absolute configurations of the amino acid units were determined by acid hydrolysis followed by derivatization with Marfey's reagent (N^α -(2,4-dinitro-5-fluorophenyl)-L-alaninamide)⁶ and subsequent HPLC analysis, comparing the chromatograms with




Figure 2. Long-range H,C -couplings and ESIMS fragments indicative of the amino acid sequence of **5**.

those of derivatives of commercially available amino acids. All amino acids were shown to be the L-enantiomers, with isoleucine being the “normal” (2*S*,3*S*) isomer.

The molecular formula of pterulamide II (**2**), $C_{34}H_{62}N_6O_6S$, was established by HRESIMS and contained one less oxygen atom than **1**. The NMR data of **2** were largely identical to those of **1**, with the only differences being located in the vicinity of the *N*-terminal group. 1H NMR spectral data for the *N*-terminus protons again showed two one-proton alkene doublets and one methyl group, but with different chemical shifts than in the spectrum of **1**. An obvious explanation for these differences, and in accordance with the molecular formula, was the presence of a (*E*)-3-(methylthio)propenoyl instead of an (*E*)-3-(methylsulfinyl)propenoyl group. Unlike the 3-methylsulfinyl group, the 3-methylthio group contains no stereocenter, so that, in contrast to **1** no doubled signals for the protons close to the *N*-terminus were observed in the 1H NMR spectrum of **2**. Two-dimensional NMR experiments, the fragmentation pattern in ESIMS, and Marfey's analysis confirmed the rest of the structure to be identical to that of **1**. Moreover, after oxidation of **2** with $NaIO_4$ the analysis of the reaction mixture by HPLC-MS showed that **1** was formed as the sole product. The 1:1 mixture of stereoisomers observed for the methylsulfinyl group in **1** poses the question as to whether this compound is of enzymatic origin or was formed by nonenzymatic oxidation of the thioether functionality to the sulfoxide, either in the fungus or later as an artifact.

Compounds **3** and **4** were closely related to the peptides **1** and **2**. Again, evaluation of the NMR data, mass spectral fragmentation patterns, and Marfey's analysis of the constituent amino acids showed that they differed from **1** only in their *N*-terminus groups. Besides the signals for the five amino acids and the *C*-terminal methylamide group, the 1H NMR spectrum of **3** contained resonances for one phenyl residue, while the spectrum of **4** showed resonances for one phenyl residue and an *E*-alkene. HMBC and COSY experiments as well as the molecular formulas $C_{37}H_{62}N_6O_6$ and $C_{39}H_{64}N_6O_6$ for **3** and **4**, respectively (HRESIMS), indicated an *N*-terminal benzoyl group for pterulamide III (**3**) and an *E*-cinnamoyl group for pterulamide IV (**4**).

The NMR data of pterulamide V (**5**) suggested a peptidic structure also for this compound, but with a different amino acid sequence from that observed for pterulamides I–IV (**1**–**4**). The 1H NMR spectrum showed signals for the α -protons of five amino acids, which again served as starting points for the identification of the amino acid units. In this case this task was severely complicated by the overlapping of three of the α -proton signals. The amino acid residues identified were an *N*-methylated isoleucyl, a valyl, and three *N*-methylated valyl units. The connectivity was established to be $NMe-Val-NMe-Val-NMe-Val-NH-Val-NMe-Ile$ using long-range H,C -couplings from the *N*-methyl groups and fragmentations in the ESI mass spectrum (Figure 2). At the *N*- and *C*-termini a benzoyl and a methylamide residue, respectively, were identified, in agreement with the required molecular formula, $C_{38}H_{64}N_6O_6$ (HRESIMS).

Pterulamide VI (**6**), with the molecular formula $C_{43}H_{72}N_6O_8$ (HRESIMS), was structurally closely related to **5**, with the only difference being an *N*-methylvaline at the *C*-terminus rather than a

Table 2. 1H and ^{13}C Data of the *N*-Terminal Groups of Pterulamides II to IV (**2**–**4**) in $CDCl_3$ ^a

| position | δ_c^b | δ_H (J in Hz) |
|----------------------------------|--------------|----------------------|
| pterulamide II: MTP ^c | | |
| CO | 165.9 | |
| α | 111.1 | 6.05 d (14.6) |
| β | 147.9 | 7.80 d (14.6) |
| S-Me | 15.0 | 2.37 s |
| pterulamide III: benzoyl | | |
| CO | 171.7 | |
| 1 | 135.7 | |
| 2,6 | 126.8 | 7.36 m |
| 3,5 | 128.6 | 7.41 m |
| pterulamide IV: cinnamoyl | | |
| CO | 166.8 | |
| α | 116.4 | 6.87 d (15.5) |
| β | 143.7 | 7.72 d (15.5) |
| C-1 | 137.7 | |
| C-2,6 | 127.7 | 7.53 m |
| C-3,5 | 128.7 | 7.37 m |
| C-4 | 129.7 | 7.37 m |

^a Chemical shifts differed significantly from those of **1** only in the *N*-terminal groups; see Supporting Information for full NMR data of all compounds. ^b ^{13}C shifts are taken from the HMBC spectra. ^c MTP = (*E*)-3-methylthiopropenoyl residue.

methylamide group. Thus, **6** is the only one of the six compounds isolated having a free *C*-terminus. Marfey's analysis showed that the amino acid residues in **5** and **6** are again based on the proteinogenic enantiomers L-valine and L-isoleucine.

Co-occurring with the linear pterulamide peptides in the same *Pterula* sp. extracts was a series of cyclic peptides that have been named the pteratides.⁷ In a cytotoxicity assay two of the pterulamides, **1** and **4**, exhibited strong activity against P388 murine leukaemia cells with IC_{50} 's of 0.55 $\mu g/mL$ (0.79 μM) and 0.95 $\mu g/mL$ (1.33 μM), respectively (pterulamide VI was not tested, due to contamination with small amounts of the strongly bioactive pteratides⁷). None of the pterulamides tested positive in antimicrobial assays against a range of Gram-positive and Gram-negative bacteria and fungi.

From several perspectives the pterulamides constitute a group of structurally unusual peptides. Besides the high degree of *N*-methylation, the pterulamides show an intriguing range of rare or unprecedented terminal groups. The 3-(methylsulfinyl)propenoyl group of **1** and the 3-(methylthio)propenoyl group of **2** have never been reported as *N*-terminal groups of natural peptides, nor are they part of any known fungal natural product. The 3-(methylthio)propenoyl group is known only from the metabolites of certain plant species, e.g., *Petasites formosanus*,⁸ and from one *Streptomyces* species,⁹ while the 3-(methylsulfinyl)propenoyl moiety is known only from plant metabolites.^{8,10} The benzoyl *N*-terminus (as observed in **3**, **5**, and **6**) is a structural feature that has, to our knowledge, never been described before as part of a linear fungal peptide, but is known from fungal cyclodepsipeptides.^{11,12} Additionally, the cinnamoyl group is part of only one group of cyclic plant peptides,¹³ but not of any natural linear peptides. A methylamide on the *C*-terminus (as in **1**–**5**) is, to our knowledge, unprecedented in a natural peptide.

Other fungal peptides formed from the nonpolar amino acids valine and isoleucine and also highly *N*-methylated are the dictyonamides from a marine alga-derived fungus¹⁴ and MHR1 and MHR2, from a marine sponge-derived *Acremonium* sp.¹⁵ However, these examples differ significantly from the pterulamides in their respective *N*- and *C*-terminal groups.

Experimental Section

General Experimental Procedures. Optical rotations were measured with a Perkin-Elmer 341. NMR spectra were recorded on a Varian (UNITY INOVA) AS-500 spectrometer (500 and 125 MHz for 1H and ^{13}C NMR, respectively), using the signals of the residual solvent protons

Table 3. NMR Data of Pterulamide V (**5**) in CDCl₃

| position | δ_C | δ_H (J in Hz) | COSY | HMBC | ROESY | TOCSY |
|-------------------|------------|----------------------|---------------------------------|---|---------------------------------------|---|
| benzoyl | | | | | | |
| CO | 171.9 | | | | | |
| 1 | 136.4 | | | | | |
| 2/6 | 126.4 | 7.30 m | 3/5 | CO, 2/6, 4 | Val1-NMe | 3/5 |
| 3/5 | 128.6 | 7.40 | 2/6 | 1, 2/6, 3/5 | | 2/6 |
| 4 | 129.6 | 7.40 | | 1, 2/6, 3/5 | | |
| Val1 ^a | | | | | | |
| CO | 170.40 | | | | | |
| α | 58.3 | 5.33 d (11.0) | β | CO, β , γ , γ' , NMe, Bz-CO | γ , γ' , NMe, Val2-NMe | β , γ , γ' |
| β | 26.8 | 2.43 m | α , γ , γ' | | NMe, γ , γ' | α , γ , γ' |
| γ | 19.5 | 0.98 d (7.0) | β | α , β , γ' | α , β | α , β |
| γ' | 18.1 | 0.93 | β | α , β , γ | α , β , NMe | α , β |
| N-Me | 32.9 | 2.87 s | | α , Bz-CO | α , β , γ' , Bz-1 | |
| Val2 ^a | | | | | | |
| CO | 171.0 | | | | | |
| α | 58.4 | 5.23 d (11.0) | β | CO, β , γ , γ' , NMe, Val1-CO | γ , γ' , Val3-NMe | β , γ , γ' |
| β | 27.2 | 2.43 m | α , γ , γ' | | NMe, γ , γ' | α , γ , γ' |
| γ | 19.6 | 0.90 | β | α , β , γ' | α , β | α , β |
| γ' | 17.8 | 0.83 | β | α , β , γ | α , β | α , β |
| N-Me | 30.5 | 3.11 s | | α , Val1-CO | β , Val1- α | |
| Val3 ^a | | | | | | |
| CO | 169.8 | | | | | |
| α | 62.4 | 4.63 | β | γ' , NMe | | β , γ , γ' |
| β | 26.3 | 2.26 m | α , γ , γ' | | NMe, γ , γ' | α , γ , γ' |
| γ | 19.2 | 0.85 | β | α , β , γ' | β | α , β |
| γ' | 18.3 | 0.74 d (6.5) | β | α , β , γ | β | α , β |
| N-Me | 30.8 | 3.07 s | | α , Val2-CO | β , Val2- α | |
| Val4 ^a | | | | | | |
| CO | 173.1 | | | | | |
| α | 53.8 | 4.69 | β , NH | CO | Ile-NMe | NH, β , γ , γ' |
| β | 31.2 | 2.00 m | α , γ , γ' | | | NH, α , γ , γ' |
| γ | 18.9 | 0.83 | β | α , β , γ' | | NH, α , β |
| γ' | 18.09 | 0.83 | β | α , β , γ | | NH, α , β |
| NH | | 6.98 bs | α | | | α , β , γ , γ' |
| Ile | | | | | | |
| CO | 170.41 | | | | | |
| α | 60.9 | 4.66 | β | CO, β -Me, NMe | | β , γ (1.30) |
| β | 31.5 | 2.11 m | α , β -Me | | NMe | α , γ , β -Me |
| β -Me | 15.4 | 0.96 | β | α , β , γ | | α , β |
| γ | 24.3 | 0.91 + 1.30 m | | | | |
| δ | 10.5 | 0.81 t (7.5) | | β , γ | | |
| N-Me | 31.0 | 3.12 s | | α , Val4-CO | β , Val4- α | |
| CON-H | | 6.45 bs | CON-Me | | | CON-Me |
| CON-Me | 25.8 | 2.74 d (4.7) | CON-H | | | CON-H |

^a Similar amino acids are numbered consecutively from N- to C-terminal end.**Table 4.** ¹H and ¹³C Data of the C-Terminal Isoleucyl–Valyl Part of Pterulamide VI (**6**) in CDCl₃^a

| position | δ_C^b | δ_H (J in Hz) |
|-------------|--------------|----------------------|
| Ile | | |
| CO | 171.8 | |
| α | 56.5 | 5.28 d (11.0) |
| β | 33.5 | 2.14 m |
| β -Me | 15.3 | 0.87 |
| γ | 24.1 | 0.94 + 1.25 m |
| δ | 10.7 | 0.82 |
| N-Me | 30.7 | 3.10 s |
| Val | | |
| CO | 171.4 | |
| α | 63.9 | 4.65 |
| β | 26.9 | 2.30 |
| γ | 18.9 | 0.79 |
| γ' | 19.5 | 1.05 d (6.0) |
| N-Me | 33.1 | 3.10 s |

^a Chemical shifts did not differ significantly from those of **5** for the remaining part of the structure; see Supporting Information for full NMR data of all compounds. ^b ¹³C shifts are taken from the HMBC spectra.

(δ 3.30 and 7.25 for MeOH-*d*₄ and CDCl₃, respectively) and the solvent carbons (δ 49.30 and 77.01 for MeOH-*d*₄ and CDCl₃, respectively) as internal references. HRESIMS were acquired using a Micromass LCT TOF mass spectrometer. Solvents used for extraction and isolation were

distilled prior to use. Cytotoxicities against P388 murine leukemia cells were measured using a standard protocol.¹⁶

Fungal Material. Fruiting bodies of an unidentified *Pterula* species were collected in the Sungkai Wildlife Forest, Perak, Malaysia (collection A), and in the Urban Nature Centre, Kuala Lumpur, Malaysia (collection B). Voucher specimens have been deposited in the collection at the School of Chemical Sciences and Food Technology, Universiti Kebangsaan Malaysia (collection A; UKM-F4794), and Institute of Biological Sciences, University of Malaya (collection B; UM-F4872). Identification of the fungal material was made by one of the authors (A.L.J.C.) based on the characteristic ageotropic, multiseptate, brown fruit bodies growing on dead sticks. Fungal thalli from the two separate collections were cut into pieces and extracted with MeOH.

Isolation. The crude extract of collection A (1.7 g) was partitioned between MeOH–H₂O (19:1) and petroleum ether. The MeOH phase was dried and partitioned between EtOAc and H₂O. Drying of the EtOAc phase gave a desalted and defatted extract (91 mg), which was fractionated by preparative HPLC (RP18, 19 × 300 mm; solvents: H₂O + 0.05% TFA (A), MeCN (B); gradient: 0 min, 75% B; 15 min, 100% B; 25 min, 100% B; 11 mL min^{−1}; UV detection at 210 nm). Fractions A, B, and C were collected at 5–8, 12–13, and 13–14 min, respectively. In all following purification steps the same solvents and detection wavelengths were used. Fraction A was submitted to preparative HPLC (Phenomenex Luna C18, 10 × 250 mm, 5 μ m); gradient elution from 10% to 80% MeCN over 25 min; 5 mL min^{−1}. Pterulamide I (**1**) was eluted after 15.5 min (1.7 mg). Fraction B was likewise subjected to preparative HPLC (Phenomenex Luna C18, 10 × 250 mm, 5 μ m; two columns in series) with isocratic elution (75%

MeCN; 4 mL min⁻¹). Pterulamide V (**5**) was eluted after 17.0 min (2.5 mg). Fraction C was purified by preparative HPLC under the same conditions as fraction B. Pterulamide VI (**6**) was eluted after 19.5 min (1.0 mg).

The crude extract of collection B (336 mg) was defatted and desalted as described above. The resultant extract (97 mg) was fractionated on an open RP18 column (LiChroprep RP18, 40–63 μ m, Merck) eluting with H₂O–MeOH (1:1), MeOH, and MeOH–CH₂Cl₂ (3:1). The combined MeOH and MeOH–CH₂Cl₂ fractions were further purified by preparative HPLC (Phenomenex Luna C18, 10 \times 250 mm, 5 μ m; gradient elution from 40% to 80% MeCN over 20 min; 5 mL min⁻¹). This yielded the following new peptides: pterulamide II (**2**; 21.0 min; 3.4 mg), pterulamide III (**3**; 21.4 min; 1.3 mg), and pterulamide IV (**4**; 23.5 min; 0.5 mg).

Pterulamide I (1): white solid; [α]_D²⁰ –92 (c 0.1, MeOH); for ¹H, ¹³C, COSY, HMBC, ROESY, and TOCSY NMR data, see Table 1; ESIMS *m/z* 721.4 (100) [M + Na]⁺, 699.5 (23) [M + H]⁺, 668.5 (3) [M – NHMe]⁺, 442.3 (27) [668 – (NHVal–NMeIle)]⁺, 369.2 (10), 353.3 (5), 329.2 (5) [442 – NMeVal]⁺, 301.2 (9); HRESIMS *m/z* 699.4484 [M + H]⁺ (calcd for C₃₄H₆₃N₆O₇S, 699.4479).

Pterulamide II (2): white solid; [α]_D²⁰ –169 (c 0.22, MeOH); for NMR data, see Table 2 and Supporting Information (Table S1); ESIMS *m/z* 705.4 (100) [M + Na]⁺, 683.4 (88) [M + H]⁺, 652.4 (5) [M – NHMe]⁺, 525.3 (5) [652 – NMeIle]⁺, 498.4 (100) [M – (MeSCH=CHCO–NMeAla)]⁺, 426.3 (30) [525 – NHVal]⁺, 313.2 (20) [426 – NMeVal]⁺, 186.0 (20) [313 – NMeIle]⁺; HRESIMS *m/z* 683.4526 [M + H]⁺ (calcd for C₃₄H₆₃N₆O₆S, 683.4530).

Pterulamide III (3): white solid; [α]_D²⁰ –159 (c 0.16, MeOH); for NMR data, see Table 2 and Supporting Information (Table S2); ESIMS *m/z* 709.5 (100) [M + Na]⁺, 687.5 (70) [M + H]⁺, 656.5 (15) [M – NHMe]⁺, 529.4 (10) [656 – NMeIle]⁺, 496.2 (10), 430.3 (30) [529 – NHVal]⁺, 317.2 (10) [430 – NMeVal]⁺, 190.1 (10) [317 – NMeIle]⁺; HRESIMS *m/z* 687.4819 [M + H]⁺ (calcd for C₃₇H₆₃N₆O₆, 687.4809).

Pterulamide IV (4): white solid; [α]_D²⁰ –270 (c 0.02, MeOH); for NMR data, see Table 2 and Supporting Information (Table S3); ESIMS *m/z* 735.5 (95) [M + Na]⁺, 713.5 (100) [M + H]⁺, 682.5 (5) [M – NHMe]⁺, 456.3 (30) [M – (NHMe–NMeIle–NHVal)]⁺, 368.3 (20), 343.2 (20) [456 – NMeVal]⁺, 216.40 (40) [343 – NMeIle]⁺; HRESIMS *m/z* 713.4944 [M + H]⁺ (calcd for C₃₉H₆₅N₆O₆, 713.4965).

Pterulamide V (5): white solid; [α]_D²⁰ –85 (c 0.1, MeOH); for ¹H, ¹³C, COSY, HMBC, ROESY, and TOCSY NMR data, see Table 3; ESIMS *m/z* 724.4 (40) [M + Na]⁺, 701.4 (100) [M + H]⁺, 670.4 (6) [M – NHMe]⁺, 444.3 (25) [670 – (NHVal–NMeIle)]⁺, 370.2 (25), 331.2 (10) [444 – NMeVal]⁺; HRESIMS *m/z* 701.4993 [M + H]⁺ (calcd for C₃₈H₆₅N₆O₆, 701.4965).

Pterulamide VI (6): white solid; [α]_D²⁰ –232 (c 0.1, MeOH); for NMR data see Table 4 and Supporting Information (Table S4); ESIMS *m/z* 823.5 (95) [M + Na]⁺, 801.5 (100) [M + H]⁺, 670.6 (10) [M – NMeValOH]⁺, 625.5 (15), 620.6 (20), 584.6 (10) [M – (Bz–NMeVal)]⁺, 576.6 (10), 444.4 (15) [670 – (NHVal–NMeIle)]⁺, 396.4 (10), 331.3 (10) [444 – NMeVal]⁺, 301.2 (10), 218.2 (20) [331 – NMeVal]⁺, 157.1 (32); HRESIMS *m/z* 801.5483 [M + H]⁺ (calcd for C₄₃H₇₃N₆O₈, 801.5490).

Preparation and Analysis of Marfey Derivatives. Pterulamides I–VI (**1–6**) were each hydrolyzed by heating the respective peptide (0.3 mg) in HCl (1 mL; 6 M) at 110 °C for 24 h. After cooling, the solution was evaporated to dryness and redissolved in H₂O (50 μ L). To each of these acid hydrolyzate solutions, or to a solution of the reference amino acid (50 μ L; 50 mM), was added a solution of FDAA (Marfey's reagent, N α -(2,4-dinitro-5-fluorophenyl)-L-alaninamide)⁶ in acetone (100 μ L of 1% (w/v) solution). After addition of NaHCO₃ solution (20 μ L; 1 M), the mixture was incubated for 1 h at 40 °C.

The reaction was stopped by addition of HCl (10 μ L; 2 M), the solvents were evaporated to dryness, and the residue was redissolved in MeOH–H₂O (1 mL; 1:1). An aliquot of this solution (10 μ L) was analyzed by HPLC (Phenomenex Luna C18, 250 \times 4.6 mm, 5 μ m; solvents: A is H₂O + 0.05% TFA, B is MeCN; linear gradient: 0 min 35% B, 30 min 45% B; 25 °C; 1 mL min⁻¹). Retention times (min) of the amino acid derivatives were as follows: L-Val (11.4), D-Val (16.2), NMe-L-Val (15.2), NMe-D-Val (18.5), NMe-L-Ile (20.4), NMe-D-Ile (25.0), NMe-L-*allo*-Ile (20.9), and NMe-D-*allo*-Ile (22.5). For the separation of the NMe-Ala derivatives different HPLC conditions were used (Phenomenex Prodigy ODS, 250 \times 4.6 mm, 5 μ m; solvents: A is H₂O + 0.05% TFA, B is MeCN; linear gradient: 0 min 45% B, 30 min 65% B; 24 °C; 1 mL min⁻¹), giving retention times of 13.6 and 13.1 min for the NMe-L-Ala and the NMe-D-Ala derivatives, respectively.

Oxidation of Pterulamide II (2). To a solution of pterulamide II (50 μ L; 10 mM in MeOH) was added an aqueous NaIO₄ solution (450 μ L; 56 mM). This mixture was left for 24 h at room temperature and then directly analyzed by HPLC-MS.

Acknowledgment. This work was supported by a fellowship within the Postdoc-Programme of the German Academic Exchange Service (DAAD) to G.L. and a Postdoctoral Fellowship from the University of Canterbury to M.I.M. We thank B. Clark for mass spectrometric analysis and G. Ellis for bioactivity assays.

Supporting Information Available: NMR data tables for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

References and Notes

- (1) Farr, D. F.; Rossman, A. Y.; Palm, M. E.; McCray, E. B. Fungal Databases, Systematic Botany & Mycology Laboratory, ARS, USDA. Retrieved January 24, 2005, from <http://nt.ars-grin.gov/fungaldata-bases>.
- (2) Engler, M.; Anke, T.; Sterner, O. *J. Antibiot.* **1995**, *48*, 884–885.
- (3) Engler, M.; Anke, T.; Sterner, O. *J. Antibiot.* **1997**, *50*, 330–333.
- (4) Engler, M.; Anke, T.; Sterner, O. *Z. Naturforsch. C* **1998**, *53*, 318–324.
- (5) Engler-Lohr, M.; Anke, T.; Hellwig, V.; Steglich, W. *Z. Naturforsch. C* **1999**, *54*, 163–168.
- (6) Marfey, P. *Carlsberg Res. Commun.* **1984**, *49*, 591–596.
- (7) Chen, C.-H.; Lang, G.; Mitova, M. I.; Murphy, A. C.; Cole, A. L. J.; Din, L. B.; Blunt, J. W.; Munro, M. H. G. *J. Org. Chem.*, in press.
- (8) Lin, Y.-L.; Mei, C.-H.; Huang, S.-L.; Kuo, Y.-H. *J. Nat. Prod.* **1998**, *61*, 887–890.
- (9) Shiomi, K.; Haneda, K.; Tomoda, H.; Iwai, Y.; Omura, S. *J. Antibiot.* **1994**, *47*, 782–786.
- (10) Tuntiwachwuttikul, P.; Pootaeng-on, Y.; Pansa, P.; Srisanpang, T.; Taylor, W. C. *Chem. Pharm. Bull.* **2003**, *51*, 1423–1425.
- (11) McCorkindale, N. J.; Baxter, R. L. *Tetrahedron* **1981**, *37*, 1795–1801.
- (12) Bringmann, G.; Lang, G.; Steffens, S.; Schaumann, K. *J. Nat. Prod.* **2004**, *67*, 311–315.
- (13) Giacomelli, S. R.; Maldaner, G.; Gonzaga, W. A.; Garcia, C. M.; da Silva, U. F.; Dalcol, I. I.; Morel, A. F. *Phytochemistry* **2004**, *65*, 933–937.
- (14) Komatsu, K.; Shigemori, H.; Kobayashi, J. *J. Org. Chem.* **2001**, *66*, 6189–6192.
- (15) Boot, C. M.; Tenney, K.; Valeriote, F. A.; Crews, P. *J. Nat. Prod.* **2006**, *69*, 83–92.
- (16) Lang, G.; Mitova, M. I.; Ellis, G.; van der Sar, S. A.; Phipps, R. K.; Blunt, J. W.; Cummings, N. J.; Cole, A. L. J.; Munro, M. H. G. *J. Nat. Prod.* **2006**, *69*, 621–624.

NP0600245